Khoueir N, et al. - Via a retrospective analytic chart review, researchers for the first time reported the results of submucosal injections of bevacizumab used in conjunction with cyanoacrylate glue sclerotherapy in hereditary hemorrhagic telangiectasia (HHT). At Lariboisiere University Hospital, they included 31 patients with HHT treated with intranasal bevacizumab and cyanoacrylate glue for refractory epistaxis from 2013 with a minimum follow-up of 6 months. Outcomes suggest the achievement of significantly reduced epistaxis and improved quality of life in HHT via administering submucosal injections of bevacizumab in conjunction with cyanoacrylate glue sclerotherapy.